Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - Инактивированные virusnih i инактивированные bakterijska cjepiva - svinje - za aktivne imunizacije svinja s 3 tjedna starosti protiv svinjske цирковирус tipa 2 (pcv2) za smanjenje količine virusa u krvi i лимфоидных tkiva i fekalne prolijevanja, uzrokovane infekcijom s ЦВС2. za aktivnu imunizaciju svinja u dobi od 3 tjedna protiv mycoplasma hyopneumoniae za smanjenje plućnih lezija uzrokovanih infekcijom s m. hyopneumoniae.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinje - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunološke za suidae - svinja (za tov) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

intervet international b.v. - svinjske цирковирус tipa 2 (pcv2) podjedinica antigen orf2, микоплазмы hyopneumoniae soja j инактивированная - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinja (za tov) - za aktivne imunizacije svinja za smanjenje виремии, virusne opterećenje u pluća i лимфоидных tkivima, izlučivanje virusa uzrokovana svinjske цирковирус tipa 2 (pcv2) infekcije i težini lezije pluća uzrokovane mycoplasma hyopneumoniae infekcije. kako bi se smanjio gubitak dnevne debljanja tijekom razdoblja završetka u lice infekcija s mycoplasma hyopneumoniae i / ili pcv2 (kao što je vidljivo u terenskim studijama).

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

intervet international b.v. - svinjski circovirus tip 2 orf2 podjedinica antigena - immunologicals for suidae, inactivated viral vaccines - svinje - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - svinjski circovirus tip 2 orf2 proteina - imunološke za suidae - svinje - za aktivne imunizacije svinja u dobi od dva tjedna od svinjske цирковирус tipa 2 (pcv2) smanjiti smrtnost, kliničke znakove, uključujući gubitak težine i poraza u лимфоидных tkivima, u svezi s ЦВС2-bolest povezana s (pcvd). osim toga, cijepljenje je pokazalo da smanjuje pcv2 nazalno prolijevanja, virusni opterećenje u krvi i limfna tkiva, te trajanje viremije. početak zaštite dolazi već dva tjedna nakon cijepljenja i traje najmanje 17 tjedana.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

ceva-phylaxia oltóanyagtermelõ zrt. - inaktivirani svinjski cirkovirus tipa 2 (pcv2) - imunološke za suidae - svinje (nazimice i krmače) - giltspassive imunizacije krmača i prasadi kroz kolostrum, nakon aktivne imunizacije krmača i popravak svinje, za smanjenje lezija u лимфоидных tkivima, u svezi s ЦВС2 infekcije i kao pomoćno sredstvo za smanjenje ЦВС2 vezane uz smrtnosti. pigletsactive imunizacija prasadi za smanjenje fekalne izlučivanje ЦВС2 i količine virusa u krvi, a kao pomoć za smanjenje ЦВС2 koji su vezani za kliničke znakove, uključujući i iscrpljenost, gubitak težine i smrtnosti, kao i za smanjenje količine virusa i poraza u лимфоидных tkiva, povezanih s infekcijom pcv2 u.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - cjepiva - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

zoetis belgium sa - cjepivo svinjske цирковирус (inaktivirano, rekombinantni) - immunologicals for suidae, inactivated viral vaccines - svinja (za tov) - za aktivne imunizacije svinja s 3 tjedna starosti protiv svinjske цирковирус tipa 2 (pcv2) za smanjenje količine virusa u krvi i лимфоидных tkiva i fekalne prolijevanja, uzrokovane infekcijom s ЦВС2.

Ευρωπαϊκή Ένωση - Κροατικά - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - svinjski circovirus tip 2 orf2 proteina - imunološke za suidae - svinje - za aktivne imunizacije svinja sa ЦВС2 primljenih mothered antitijela u dobi od 2 tjedna protiv svinjske цирковирус tipa 2 (ЦВС2),.